Subject: GLP-1 Agonist Trulicity PA with Limit Policy 1193-C UDR 05-2024

Drug
GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR AGONIST
TRULICITY *(dulaglutide)*

Policy:

FDA-APPROVED INDICATIONS
Trulicity is indicated:
- As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
- To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.

Limitations of Use
- Has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
- Not for treatment of type 1 diabetes mellitus.
- Not recommended in patients with severe gastrointestinal disease, including severe gastroparesis.

Compendial Uses
Advanced chronic kidney disease (CKD) in adults with type 2 diabetes mellitus[6]

COVERAGE CRITERIA

Type 2 Diabetes Mellitus
Authorization may be granted for a diagnosis of type 2 diabetes mellitus when the following criteria is met:
- The patient has NOT been receiving a stable maintenance dose of a GLP-1 (glucagon-like peptide 1) Agonist for at least 3 months [Note: Examples of GLP-1 Agonists are Adlyxin, Bydureon, Byetta, Ozempic, Rybelsus, Trulicity, Victoza] and ONE of the following criteria are met:
  - The patient has experienced an inadequate treatment response, intolerance, or has a contraindication to metformin
  - The patient requires combination therapy AND has an A1C of 7.5 percent or greater
  - The patient has a diagnosis of advanced chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] less than 30 mL/min/1.73m^2)
  - The patient has established cardiovascular disease or multiple cardiovascular risk factors

CONTINUATION OF THERAPY

Type 2 Diabetes Mellitus
Authorization may be granted for a diagnosis of type 2 diabetes mellitus when the following criteria is met:
- The patient has been receiving a stable maintenance dose of a GLP-1 (glucagon-like peptide 1) Agonist for at least 3 months [Note: Examples of GLP-1 Agonists are Adlyxin, Bydureon, Byetta, Ozempic, Rybelsus, Trulicity, Victoza] and ONE of the following criteria are met:
  - The patient has demonstrated a reduction in A1C since starting GLP-1 (glucagon-like peptide 1) Agonist therapy
  - The patient has a diagnosis of advanced chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] less than 30 mL/min/1.73m^2)
  - The patient has established cardiovascular disease or multiple cardiovascular risk factors

QUANTITY LIMITS APPLY
4 pens (2 mL) per 21 days* or 12 pens (6 mL) per 63 days*
**The duration of 21 days is used for a 28-day fill period and 63 days is used for an 84-day fill period to allow time for refill processing.*

DURATION OF APPROVAL (DOA)
- 1193-C: DOA: 36 months

Place of Service:

Outpatient

The above policy is based on the following references:

1. Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; December 2022.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. https://online.lexi.com. Accessed March 11, 2024.
3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 03/11/2024).
4. Blonde L, Umpierrez GE, Reddy SS et. al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan – 2022 Update. Endocr Pract. 2022;28(10):923-1049.
5. Davies MJ, Aroda VR, Collins BS, et. al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786.
6. American Diabetes Association Professional Practice Committee. American Diabetes Association, Standards of Care in Diabetes – 2024. Diabetes Care. 2024;47(Suppl. 1):S1-S322.
7. Samson SL, Vellank P, Blonde L, et. Al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm 2023 Update. Endocr Pract. 2023; 29: 305-340.

October 27, 2024